2 results found

Jiangyang Li, Xianfeng Lu, Shuai Yue, Ruyi Hang, Xiaoyan Dai, Xunjie Kuang, Wei Guo, Zhou Huang, Yanli Xiong, Mengxia Li

Non-small cell lung cancer (NSCLC) patients carrying HER2 20ins exon 20 insertion (HER2 20ins) are poorly respond to conventional therapies and pan HER inhibitors. Trastuzumab Deruxtecan (T-DXd) has b...

Scientific Reports 2026-04-22 rs-8854444
HER2 (ERBB2) NSCLC Deruxtecan (T-DXd DS-8201) Genomic instability Immune microenvironment

Pitithat Puranachot, Thivaratana Sinthuwiwat, Priyavudh Herabutya, Kanthida Jangyubol, Bongkod Petcharat, Jutamas Yimnoon, Jitsopin Phadungsut, Chayanee Samdaengpan, Chumut Phanthunane

Background: Accurately predicting treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) remains a significant clinical challenge. While circulating tumor DNA (ctDNA) within p...

BMC Personalized Medicine 2026-04-21 rs-9258115
Liquid biopsy monitoring Cell-free DNA Non-small cell lung cancer Progression-free survival Copy-number alterations cfDNA fragmentation Low-coverage whole-genome sequencing
Back to Top
Home
Browse
Submit
About
0.034300s